Access
To read this story in full you will need to login or make a payment (see right).
Insight
Nature 436, 953-960 (18 August 2005) | doi:10.1038/nature04080; Published online 17 August 2005
Open Innovation Challenges
- More Challenges
- Powered by:
nature jobs
Assoc. Scientific Manager / Scientific Manager - Biopharmaceutics
- Syngene International
- Bangalore, Karnataka 560099 India
Assistant Editor – Nature Immunology
- Nature Publishing Group
- New York, NY United States
review article Challenges and successes in developing new therapies for hepatitis C
Raffaele De Francesco1 & Giovanni Migliaccio1
Abstract
Hepatitis C virus (HCV) will continue to be a serious global health threat for many years to come because of the chronic nature of the infection, its high prevalence and the significant morbidity of the resulting disease. Recently, a small number of molecules have produced encouraging results in proof-of-concept clinical trials. At the same time, preclinical evidence is accumulating that development of resistance will eventually limit the efficacy of new drugs. Thus, combinations of multiple agents will be required to treat chronic HCV infection.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Hepatitis HCV variability, the immune system and resistance to antiviral drugsNature Reviews Gastroenterology & Hepatology News and Views (01 Jul 2009)
Virology Fresh assault on hepatitis CNature News and Views (13 Nov 2003)
